# EDGAR Filing Document

**Accession Number:** 0001815620
**File Stem:** 0000950170-25-109928
**Filing Date:** 2025-8
**Character Count:** 9929
**Document Hash:** 3abdf33d95185289d7e120f2cc4f1aeb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-109928.hdr.sgml**: 20250819

**ACCESSION NUMBER**: 0000950170-25-109928

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20250819

**FILED AS OF DATE**: 20250819

**DATE AS OF CHANGE**: 20250819

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Opthea Ltd
- **CENTRAL INDEX KEY:** 0001815620
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39621
- **FILM NUMBER:** 251229596

**BUSINESS ADDRESS:**
- **STREET 1:** LEVEL 4
- **STREET 2:** 650 CHAPEL STREET
- **CITY:** SOUTH YARRA, VICTORIA
- **STATE:** C3
- **ZIP:** 3141
- **BUSINESS PHONE:** 61 3 9826 0399

**MAIL ADDRESS:**
- **STREET 1:** LEVEL 4
- **STREET 2:** 650 CHAPEL STREET
- **CITY:** SOUTH YARRA, VICTORIA
- **STATE:** C3
- **ZIP:** 3141

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM 6-K** 

------

**REPORT OF FOREIGN ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the month of August, 2025** 

**Commission File No. 001-39621** 

------

**OPTHEA LIMITED**

**(Translation of registrant's name into English)** 

------

**Level 4**

**650 Chapel Street**

**South Yarra, Victoria, 3141**

**Australia**

**(Address of registrant's principal executive office)** 

------

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

------

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [**<u>Opthea Appendix 2A</u>**](opt-ex99_1.htm) |

---

------

**<u>SIGNATURES</u>** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | |
|:---|:---|
| **OPTHEA LIMITED** | **OPTHEA LIMITED** |
| (Registrant) | (Registrant) |
| By: | /s/ Frederic Guerard |
| Name: | Frederic Guerard |
| Title: | Chief Executive Officer  |

---

Date: 08/19/2025

------

## Exhibit 99.1

**Exhibit 99.1**

![img260626642_0.jpg](img260626642_0.jpg)

**ASX, Nasdaq and Media Release**

August 19, 2025

**Announcement Summary**

------

**Entity name**

OPTHEA LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

Tuesday August 19, 2025

**The +securities to be quoted are:**

Other

**Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.**

<u>Securities issues as part of settlement of a development funding agreement.</u>

**Total number of +securities to be quoted**

---

| | | | |
|:---|:---|:---|:---|
| **ASX +security**<br>**code** | **Security description** | **Number of +securities to**<br>**be quoted** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Issue date** |
| OPT | ORDINARY FULLY PAID | 136,661,003 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18/08/2025 |

---

Refer to next page for full details of the announcement

------

![img260626642_1.jpg](img260626642_1.jpg)

Part 1 - Entity and announcement details

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.1 Name of entity**

OPTHEA LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

---

| | |
|:---|:---|
| **1.2 Registered number type** | **Registration number** |
| ABN | 32006340567 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.3 ASX issuer code**

OPT

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.4 The announcement is**

New announcement

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.5 Date of this announcement**

19/8/2025

------

![img260626642_1.jpg](img260626642_1.jpg)

**Part 2 - Type of Issue**

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.1 The +securities to be quoted are:**

Other

**Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.2 The +class of +securities to be quoted is:**

Additional +securities in a class that is already quoted on ASX ("existing class")

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.3 c Have these +securities been offered under a +disclosure document or +PDS?**

No

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.3 d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B**

<u>Securities issues as part of settlement of a development funding agreement.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:**

Not applicable - the entity has arrangements in place with the holder that ensure the securities cannot be on-sold within 12 months in a manner that would breach section 707(3) or 1012C(6)

------

![img260626642_1.jpg](img260626642_1.jpg)

Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

------

**Additional +securities to be quoted in an existing class ASX +security code and description**

OPT : ORDINARY FULLY PAID

**Issue date**

18/8/2025

**Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

**Issue details**

**Number of +securities to be quoted**

136,661,003

**Are the +securities being issued for a cash consideration?**

No

**Please describe the consideration being provided for the +securities**

<u>The subscribers terminate the development funding agreement and release all actions, suits damages, and other claims against Opthea in relation to the development funding agreement</u>

**Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.000000 **Any other information the entity wishes to provide about the +securities to be quoted**

**The purpose(s) for which the entity is issuing the securities**

Other

**Please provide additional details**

<u>The settlement of the development funding agreement between Opthea Limited and the subscribers, including the termination of the development funding agreement and release of all suits, actions, damages and other claims.</u>

------

![img260626642_1.jpg](img260626642_1.jpg)

Part 4 - Issued capital following quotation

------

**Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:**

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)**

---

| | |
|:---|:---|
| **ASX +security code and description** | **Total number of**<br>**+securities on issue** |
| OPT : ORDINARY FULLY PAID | 1367978011 |
| OPTOA : OPTION EXPIRING 31-AUG-2025 | 97787612 |
| OPTOB : OPTION EXPIRING 30-JUN-2026 | 189426682 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)**

---

| | |
|:---|:---|
| **ASX +security code and description** | **Total number of**<br>**+securities on issue** |
| OPTAD : PERFORMANCE RIGHTS | 2900000 |
| OPTAL : OPTION EXPIRING 19-FEB-2034 EX USD 3.03 | 250000 |
| OPTAA : OPTION EXPIRING 31-MAR-2034 EX USD 4.14 | 27000 |
| OPTAB : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 41370950 |
| OPTAC : ADS EXPIRING VARIOUS DATES EX VARIOUS PRICES | 11660578 |

---

------

![img260626642_1.jpg](img260626642_1.jpg)

Part 5 - Other Listing Rule requirements

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?**

No

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?**

No

**5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

Yes

**5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

<u>136,661,003</u>

**5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**

No

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Investor Inquiries** | &nbsp;&nbsp;***Join our email database to receive program updates:*** |
| &nbsp;&nbsp;Email: info@opthea.com<br>Web: www.opthea.com<br>| &nbsp;&nbsp;Tel: +61 (0) 3 9826 0399<br>Email: info@opthea.com<br>Web: www.opthea.com<br>**Source: Opthea Limited** |

---

------